# US 2025/0144220 A1 · Conjugate for preventing and treating viral infections and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144220 A1
- Document ID: US20250144220A1
- Status: Published application
- Kind: A1
- Application number: 18/719,549
- Filed: 2022-12-29
- Published: 2025-05-08
- Earliest claimed: 2021-12-30
- Assignees: Suzhou Ark Biopharmaceutical Co., Ltd.
- Applicants: Suzhou Ark Biopharmaceutical Co., Ltd.
- Inventors: Cheng PENG; Guowei SONG; Zhidong SONG; Shuai YUAN; Weikang LING; Jia MENG; Ta SUN; Zhao GAO; Gang ZOU; Haiging YUAN; Zhen Jim WU
- Web page: https://patentgrep.com/patent/US20250144220A1

## CPC

- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- A61K 31/13: Amines {(A61K31/04 takes precedence)}
- A61K 31/196: the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A61K 31/215: of carboxylic acids
- A61K 31/351: not condensed with another ring
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/5383: ortho- or peri-condensed with heterocyclic ring systems
- A61K 39/42: viral
- A61K 47/543: {Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine}
- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61K 47/68: the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61P 31/16: for influenza or rhinoviruses
- C07D 309/28: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 405/14: containing three or more hetero rings
- C07K 2317/52: Constant or Fc region; Isotype
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to a conjugate for preventing and treating viral infections and a use thereof, and in particular, to a protein-anti-influenza compound conjugate having a structure of formula I-1 or a pharmaceutically acceptable salt, an ester, an isomer, a solvate, a prodrug or an isotope label thereof. The conjugate has small molecules (D1 and D2) linked, by means of linkers (L1 and L2) to an Fc monomer, an Fc domain, an Fc linker peptide, an albumin or an albumin linker peptide (E) and having anti-influenza virus activity. The conjugate or the intermediate compound of the present invention has significant anti-influenza virus activity, and meanwhile, has excellent in vitro/in vivo pharmacokinetic property and safety and has good clinical application prospects.

## Claims

### Claim 1

A conjugate of formula I-1, or a pharmaceutically acceptable salt, ester, isomer, solvate, prodrug or isotopically labeled derivative thereof,
wherein,
m is 1 or 2;
n is an integer from 1 to 20, preferably an integer from 1 to 10, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; and two n's are identical;
each of D1 and D2 is an anti-influenza virus small molecule drug, and is independently selected from a compound having an anti-influenza activity as shown in formulae D-1-1 to D-1-8:
R1 is selected from OH, NH2, —NH(═NH)NH2 and —NHC(═NH)NHR6;
R2 and R3 are each independently selected from H, OH, F, Cl and Br;
R4 is selected from —COOH, —P(═O)(OH)2 and —SO3H;
R5 is selected from —COC1-6 alkyl, —COC1-6 haloalkyl, —SO2C1-6 alkyl, and —SO2C1-6 haloalkyl; preferably selected from —COCH3, —COCF3, and —SO2CH3;
X is selected from O and S;
R6 is selected from the following groups:
Y is selected from the following groups, wherein “(attached to L1)” specifies the end of the group Y attached to the end of L1, wherein N denotes an atom within the ring when drawn inside the ring:
ring A is selected from C3-C20 cycloalkyl, substituted C3-C20 cycloalkyl, C3-C20 cycloalkenyl, substituted C3-C20 cycloalkenyl, C6-C15 aryl, 3- to 20-membered heterocycloalkyl, substituted 3- to 20-membered heterocycloalkyl, substituted C6-C15 aryl and substituted 5- to 15-membered heteroaryl;
R groups are each independently selected from H, deuterium, optionally substituted C1-C20 alkyl, optionally substituted C2-C20 streptenyl, optionally substituted C3-C20 cycloalkyl, optionally substituted 3- to 20-membered heterocycloalkyl, optionally substituted C6-C15 aryl, and optionally substituted 5- to 15-membered heteroaryl;
q is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;
L1 is a linker attached to the drug (D1 or D2) and L2, and includes but not limited to following structures:
wherein bonds at left and right ends of the following structures are attached to an oxygen atom of the drug and a bond marked by the wavy line in the middle is attached to L2,
wherein:
W is selected from O, S, NRb, CH2 or absent;
Ra and Rb are each independently selected from H, optionally substituted C1-C20 alkyl, optionally substituted C2-C20 alkenyl;
y1 and y2 are each independently 0, 1, 2, 3, 4, 5 or 6;
q1 and q2 are each independently selected from 1, 2, 3, 4, 5 and 6;
or
L1 is selected from following structures:
L2 is a linker attaching L1 and E (Fc monomer, Fc structural domain, Fc-binding peptide, albumin, or albumin-linking peptide) and having a structure sleeted from formula L2-1 to L2-15, wherein (L1) and (E) denote ends of L2 connected to L1 and E, respectively:
L2 structure No.
Structure
L2-1
L2-2
L2-3
L2-4
L2-5
L2-6
L2-7
L2-8
L2-9
L2-10
L2-11
L2-12
L2-13
L2-14
L2-15
wherein,
Z is NR, S or O;
R are each independently selected from hydrogen, deuterium, optionally substituted C1-C20 alkyl, optionally substituted C2-C20 chain alkenyl, optionally substituted C3-C20 cycloalkyl, optionally substituted 3- to 20-membered heterocycloalkyl, optionally substituted C6-C15 aryl and optionally substituted 5- to 15-membered heteroaryl;
s and t are integers from 1 to 20; such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;
y is 0 or 1;
Q is N or CH;
p is 0, 1, 2, 3, 4, 5, 6, 7 or 8;
E is an antibody or an antibody fragment thereof, an Fc structural domain monomer, an Fc structural domain, an Fc-binding peptide, an albumin or an albumin-linking peptide, and comprises an amino acid sequence of any one of SEQ ID Nos. 1-68 or an amino acid sequence that is at least 95% identical to any one of SEQ ID Nos. 1-68.

### Claim 2 (depends on 1)

The conjugate of claim 1, or a pharmaceutically acceptable salt, ester, isomer, solvate, prodrug or isotopically labeled derivative thereof,
wherein
m is 1 or 2;
n is an integer from 1 to 10;
each of D1 and D2 is independently selected from the compound having an anti-influenza activity as shown in the formulae D-1-1 to D-1-8;
D1 and D2 are covalently attached to L1 that is covalently attached to L2, and L2 is covalently attached to E;
E is selected from the Fc structural domain monomer, the Fc structural domain, the Fc-binding peptide, the albumin or the albumin-linking peptide.

### Claim 3 (depends on 1)

The conjugate of claim 1, or a pharmaceutically acceptable salt, ester, isomer, solvate, prodrug or isotopically labeled derivative thereof, wherein the conjugate has a structure of formula I-1-1 to I-1-8:
Conjugate No.
Structure
I-1-1
I-1-2
I-1-3
I-1-4
I-1-5
I-1-6
I-1-7
I-1-8
wherein each variable is as defined in claim 1.

### Claim 4 (depends on 1)

The conjugate of claim 1, or a pharmaceutically acceptable salt, ester, isomer, solvate, prodrug or isotopically labeled derivative thereof, wherein the conjugate has a structure of formula I-1-A to I-1-D:
No.
Structure
I-1-A
I-1-B
I-1-C
I-1-D
wherein each variable is as defined in claim 1.

### Claim 5 (depends on 1)

The conjugate of claim 1, or a pharmaceutically acceptable salt, ester, isomer, solvate, prodrug or isotopically labeled derivative thereof, wherein the conjugate has a structure of formula C-1 to C-115:
Conju-
gate
No.
Conjugate Structure
C-1
C-2
C-3
C-4
C-5
C-6
C-7
C-8
C-9
C-10
C-11
C-12
C-13
C-14
C-15
C-16
C-17
C-18
C-19
C-20
C-21
C-22
C-23
C-24
C-25
C-26
C-27
C-28
C-29
C-30
C-31
C-32
C-33
C-34
C-35
C-36
C-37
C-38
C-39
C-40
C-41
C-42
C-43
C-44
C-45
C-46
C-47
C-48
C-49
C-50
C-51
C-52
C-53
C-54
C-55
C-56
C-57
C-58
C-59
C-60
C-61
C-62
C-63
C-64
C-65
C-66
C-67
C-68
C-69
C-70
C-71
C-72
C-73
C-74
C-75
C-76
C-77
C-78
C-79
C-80
C-81
C-82
C-83
C-84
C-85
C-86
C-87
C-88
C-89
C-90
C-91
C-92
C-93
C-94
C-95
C-96
C-97
C-98
C-99
C-100
C-101
C-102
C-103
C-104
C-105
C-106
C-107
C-108
C-109
C-110
C-111
C-112
C-113
C-114
C-115
where n is as defined in claim 1, and protein is E as defined in claim 1.

### Claim 6 (depends on 1)

The conjugate of claim 1, or a pharmaceutically acceptable salt, ester, isomer, solvate, prodrug or isotopically labeled derivative thereof, wherein a ratio of n to m is from 1 to 20, preferably from 2 to 10, such as 2, 3, 4, 5, 6, 7, 8, 9 or 10.

### Claim 7 (depends on 1)

The conjugate of claim 1, or a pharmaceutically acceptable salt, ester, isomer, solvate, prodrug or isotopically labeled derivative thereof, wherein the conjugate has an average DAR value between 0.5 and 10.0.

### Claim 8 (depends on 1)

The conjugate of claim 1, or a pharmaceutically acceptable salt, ester, isomer, solvate, prodrug or isotopically labeled derivative thereof, wherein E comprises an Fc structural domain monomer or an Fc structural domain containing said Fc structural domain monomer, wherein said Fc structural domain monomer comprises or consists of an amino acid sequence of any one of SEQ ID Nos. 1-68 or an amino acid sequence that is at least 95% identical to any one of SEQ ID Nos. 1-68.

### Claim 9 (depends on 1)

The conjugate of claim 1, or a pharmaceutically acceptable salt, ester, isomer, solvate, prodrug or isotopically labeled derivative thereof, wherein E is recognizable for viral surface antigens, such as CR6261, CR8020, MEDI8897, Palivizumab, SD38, or
the Fc structural domain monomer may be an Fc structural domain monomer of an antibody subtype (such as, IGHG1*01 (such as G1m(za)), IGHG1*07 (such as G1m(zax)), IGHG1*04(such as G1m(zav)), IGHG1*03(G1m(f)), IGHG1*08 (such as G1m(fa)), IGHG2*01, IGHG2*02, IGHG2*06, IGHG3*01, IGHG3*04, IGHG3*05, IGHG3*09, IGHG3*10, IGHG3*11, IGHG3*12, IGHG3*06, IGHG3*07, IGHG3*08, IGHG3*13, IGHG3*03, IGHG3*14, IGHG3*15, IGHG3*16, IGHG3*17, IGHG3*18, IGHG3*19, IGHG2*04, IGHG4*01, IGHG4*02, IGHG4*03) of any kind of immunoglobulins.

### Claim 10 (depends on 1)

The conjugate of claim 1, or a pharmaceutically acceptable salt, ester, isomer, solvate, prodrug or isotopically labeled derivative thereof, wherein the conjugate has a structure below:
wherein n is as defined in claim 1.

### Claim 11 (depends on 1)

A compound of formula I-2, or a pharmaceutically acceptable salt, ester, isomer, solvate, prodrug or isotopically labeled derivative thereof,
wherein L1, D1 and D2 are as defined in formula I-1 of claim 1,
L3 is selected from following structures:
L3
structure
No.
Structure
L3-1
L3-2
L3-3
L3-4
L3-5
L3-6
L3-7
L3-8
L3-9
L3-10
L3-11
L3-12
L3-13
L3-14
L3-15
wherein each variable such as Z, R, Q, s, y, p is as defined for L2 in claim 1.

### Claim 12 (depends on 11)

The compound of Formula I-2 of claim 11, or a pharmaceutically acceptable salt, ester, isomer, solvate, prodrug or isotopically labeled derivative thereof, wherein said compound has a structure of Formula C-Inter-1 to C-Inter-115:
No.
Structure
C-Inter-1
C-Inter-2
C-Inter-3
C-Inter-4
C-Inter-5
C-Inter-6
C-Inter-7
C-Inter-8
C-Inter-9
C-Inter-10
C-Inter-11
C-Inter-12
C-Inter-13
C-Inter-14
C-Inter-15
C-Inter-16
C-Inter-17
C-Inter-18
C-Inter-19
C-Inter-20
C-Inter-21
C-Inter-22
C-Inter-23
C-Inter-24
C-Inter-25
C-Inter-26
C-Inter-27
C-Inter-28
C-Inter-29
C-Inter-30
C-Inter-31
C-Inter-32
C-Inter-33
C-Inter-34
C-Inter-35
C-Inter-36
C-Inter-37
C-Inter-38
C-Inter-39
C-Inter-40
C-Inter-41
C-Inter-42
C-Inter-43
C-Inter-44
C-Inter-45
C-Inter-46
C-Inter-47
C-Inter-48
C-Inter-49
C-Inter-50
C-Inter-51
C-Inter-52
C-Inter-53
C-Inter-54
C-Inter-55
C-Inter-56
C-Inter-57
C-Inter-58
C-Inter-59
C-Inter-60
C-Inter-61
C-Inter-62
C-Inter-63
C-Inter-64
C-Inter-65
C-Inter-66
C-Inter-67
C-Inter-68
C-Inter-69
C-Inter-70
C-Inter-71
C-Inter-72
C-Inter-73
C-Inter-74
C-Inter-75
C-Inter-76
C-Inter-77
C-Inter-78
C-Inter-79
C-Inter-80
C-Inter-81
C-Inter-82
C-Inter-83
C-Inter-84
C-Inter-85
C-Inter-86
C-Inter-87
C-Inter-88
C-Inter-89
C-Inter-90
C-Inter-91
C-Inter-92
C-Inter-93
C-Inter-94
C-Inter-95
C-Inter-96
C-Inter-97
C-Inter-98
C-Inter-99
C-Inter-100
C-Inter-101
C-Inter-102
C-Inter-103
C-Inter-104
C-Inter-105
C-Inter-106
C-Inter-107
C-Inter-108
C-Inter-109
C-Inter-110
C-Inter-111
C-Inter-112
C-Inter-113
C-Inter-114

### Claim 13 (depends on 1)

A Pharmaceutical composition comprising the conjugate of formula I-1 as claimed in claim 1, or a pharmaceutically acceptable salt, ester, isomer, solvate, prodrug or isotopically labeled derivative thereof, and optionally one or more other therapeutic agents, such as chemotherapeutic agents, angiogenesis inhibitors, cytokines, cytotoxic agents, other antibodies, other small molecule drugs or immunomodulators (e.g., immune checkpoint inhibitors or agonists), and optionally pharmaceutically acceptable excipients.

### Claim 14 (depends on 1)

A method for the prevention or treatment of a subject having a viral infection or at a risk of having a viral infection, comprising administering to the subject, for example by injection, an effective amount of the conjugate of formula I-1 as claimed in claim 1, a pharmaceutically acceptable salt, ester, isomer, solvate, prodrug or isotopically labeled derivative thereof.

### Claim 15 (depends on 14)

The method of claim 14, wherein
the viral infection is an infection caused by an influenza virus or a parainfluenza virus;
preferably, the viral infection is an infection caused by influenza virus A, B or C, or parainfluenza virus;
preferably, the subject having a viral infection or at a risk of having a viral infection may be a subject with an immune system deficiency;
preferably, the subject having a viral infection or at a risk of having a viral infection may be a subject who is or will be treated with an immunosuppressive agent, preferably, the subject having a viral infection or at a risk of having a viral infection may be a subject diagnosed with an immunosuppression disease;
preferably, the subject diagnosed with an immunosuppression disease has cancer or acquired immunodeficiency syndrome;
preferably, the subject diagnosed with an immunosuppression disease has leukemia, lymphoma, humoral immunodeficiency, T-cell deficiency, complement deficiency or multiple myeloma;
preferably, the subject is a subject undergoing or about to undergo a hematopoietic stem cell transplant;
preferably, the subject is a subject undergoing or about to undergo an organopoietic transplant; and/or
preferably, the subject may be at a risk of a secondary infection.

### Claim 16 (depends on 1)

A method for preventing a secondary infection of a subject caused by an influenza virus infection, comprising administering to the subject, for example by an injection, an effective amount of the conjugate of formula I-1 as claimed in claim 1, a pharmaceutically acceptable salt, ester, isomer, solvate, prodrug or isotopically labeled derivative thereof,
preferably, said secondary infection is a respiratory infection;
preferably, said secondary infection is associated with pneumonia;
preferably, said secondary infection is a bacterial, or viral, or fungal infection;
preferably, said bacterial infection is an infection caused by methicillin-resistant Staphylococcus aureus; preferably, said bacterial infection is an infection caused by Streptococcus pneumoniae;
preferably, the conjugate of formula I-1 or the compound of formula I-2, or pharmaceutically acceptable salt, ester, isomer, solvate, prodrug or isotopically labeled derivative thereof, is administrated by an intramuscular injection, intravenous injection, intradermal injection, intra-arterial injection, intraperitoneal injection, intra-lesional injection, intracranial injection, intra-articular injection, intrapleural injection, intratracheal injection, intraprostatic injection, intranasal injection, intravitreous injection, intravaginal injection, intrarectal injection, local injection, intra-tumor injection, intraperitoneal injection, subcutaneous injection, subconjunctival injection, intracapsular injection, mucosal injection, intrapericardial injection, intra-umbilical injection, intra-ocular injection, oral, local inhalation, injection or infusion,
preferably, the conjugate of formula I-1 or the compound of formula I-2, or pharmaceutically acceptable salt, ester, isomer, solvate, prodrug or isotopically labeled derivative thereof, combines with another therapeutic agent in administration or in the preparation of a medicament;
preferably, the another therapeutic agent is an antiviral drug;
preferably, the antiviral drug is baloxavir, pimodivir, oseltamivir, zanamivir, peramivir, laninamivir, amantadine, MEDI8852 or rimantadine;
preferably, another drug used by the subject is an antiviral vaccine;
preferably, the antiviral drug and the conjugate of formula I-1 or the compound of formula I-2, or pharmaceutically acceptable salt, ester, isomer, solvate, prodrug or isotopically labeled derivative thereof, are sequentially administered, for example, by injection to the subject; and/or
preferably, the antiviral drug and the conjugate of formula I-1 or the compound of formula I-2, or pharmaceutically acceptable salt, ester, isomer, solvate, prodrug or isotopically labeled derivative thereof, are simultaneously administered, for example by injection, to the subject.
